Disease relevance of Luxabendazole

• The mutagenic properties of Luxabendazole were investigated in the in vitro Ames Salmonella and E. coli tests [1].
• PROCEDURE: Pharmacokinetics were determined after oral and i.v. administration of luxabendazole at a dose of 10 mg/kg of body weight [2].

High impact information on Luxabendazole

• Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep [2].
• CONCLUSIONS: Results suggest that luxabendazole is moderately absorbed from the gastrointestinal tract in sheep, is widely distributed into extravascular compartments, and is cleared slowly [2].
• Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests [1].
• The intestinal absorption of Luxabendazole in rats [3].
• Luxabendazole at 7.5, 10.0, and 12.5 mg/kg proved 100% effective in removing adult worms of the genera Haemonchus, Ostertagia, Trichostrongylus, Cooperia and Nematodirus as well as tissue-associated larval stages of gastrointestinal nematodes of the abomasal mucosa [4].

Biological context of Luxabendazole

• Pharmacokinetics of intravenous luxabendazole in rabbits: influence of the enterohepatic circulation [5].

Analytical, diagnostic and therapeutic context of Luxabendazole

• Determination of luxabendazole in biological fluids by high-performance liquid chromatography [6].
• After oral administration, luxabendazole was slowly absorbed from the gastrointestinal tract [2].

References